Could Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX)’s run strain expectations?


Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock had a weekly volatility of 4.89% and a monthly volatility of 3.38%. Lexicon Pharmaceuticals, Inc. LXRX shares float stands at 98.69M.

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

Recently, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) reported that Lexicon Pharmaceuticals, Inc. quarterly Return on Assets is -29.10%, while quarterly Return on Equity was -81.50% and quarterly Return on Investment was -53.00%.

Gross Margin in the past quarter was 99.70%. Current ratio was 2.00 while quick ratio was 2.00.

The firm’ Total Debt/Equity stood at 0.75 while Long Term Debt/Equity was 0.63.

The firm’s stock 50-Day High is $-8.10% and a 50-Day Low of $10.31%. 20-Day Simple Moving Average was $-0.75% while 50-Day SMA was $-0.05%.

The firm announced EPS of $-1.36. This shows an EPS growth quarter over last quarter was 0.70%. EPS for the year was $-9.60%. For the last 5-year, the stock has recorded an average EPS growth of 10.60% and EPS growth for imminent year is projected to be 39.60% .

The firm’s monthly average volume for the reported quarter was 843.33K and 843.33K for the full fiscal year. The relative volume was 0.97 for the quarter and 0.97 for the full fiscal year.

The stock’s 50-Day High in the last quarter was $-8.10% while the 50-Day Low was $10.31%. In the last fiscal year, the stock hit a 52-Week High of $-24.21% and a 52-Week Low of $14.30%.

The firm’s insider ownership was 0.20% and institutional ownership was 95.20%. Total institutional transactions amounted to 3.23%. Sales growth QoQ was 46.40%.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced today that new clinical data for sotagliflozin will be presented at the upcoming 77th American Diabetes Association (ADA) Scientific Sessions in San Diego, CA, from June 9-13. The four accepted abstracts, including two oral presentations, reflect Lexicon’s efforts to improve current approaches to the clinical management of type 1 diabetes.